Trump administration halts global supply of HIV, malaria, tuberculosis drugs
.png)
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to countries supported by the agency.
USAID and its contractors fund programs across the globe that help millions of individuals in the fight against diseases such as HIV/AIDS, malaria, and tuberculosis, particularly in low-income nations. In 2023, the US provided USD$72 billion in aid around the world, and 42% of all global humanitarian aid. The funds provide assistance in clean water access and overall healthcare infrastructure. US Consulting firm Chemonics received one such memo, demanding the firm’s work in providing medical aid and contraception and maternal health supplies to stop.
Former head of global health at USAID Atul Gawande commented, “This is catastrophic. Donated drug supplies keeping 20 million people living with HIV alive – that stops today.” Not only will millions of individuals be prevented from receiving life-saving treatments, Gawande also warned against potential transmission and emergence of drug-resistant strains of viruses like HIV. Other partners of USAID have also received notices to halt work, many of whom are now unable to deliver medicines to clinic despite being in stock, or even open clinics that are funded by the US.
Just hours taking office on January 20, 2025, Trump ordered a 90-day pause on foreign aid to review policy priorities, putting between 57–60 senior career individuals on leave at USAID. This foreign aid includes work encompassing 6.5 million orphans and vulnerable children living with HIV in 23 countries, and the career officials affected include those working in water security, children’s education, and digital technology transformation.
In an interview with The Guardian, former USAID China policy lead Francisco Bencosme stated “This decision undermines our national security and emboldens our adversaries. Instead of focusing on China, North Korea, or Russia, the Trump administration is going after public servants who have served multiple administrations – including the first Trump administration.”
President of Refugees International and former USAID official Jeremy Konyndyk also commented that “If this is not reversed, it will wreck US foreign aid…it would permanently weaken USAID.”
Sources
1. Trumper order set to halt supply of HIV, malaria drugs to poor countries, sources say [Accessed January 29, 2025] https://www.reuters.com/business/healthcare-pharmaceuticals/trump-order-set-halt-supply-hiv-malaria-drugs-poor-countries-sources-say-2025-01-28/
2. Trump administration puts about 60 USAid officials on leave after aid freeze [Accessed January 29, 2025] https://www.theguardian.com/us-news/2025/jan/27/trump-usaid-workers-on-leave-aid-freeze
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig... -
News Medtech company Beta Bionics targets USD$616 million IPO valuation
California-based insulin delivery device manufacturer Beta Bionics have stated their intentions to target an IPO valuation of USD$616 million in the United States, signalling an optimistic recovery of medtech and biotech public listings.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance